AUG 1 6 2002 W

RFCEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE AND MEDICAL

In re Application of:

Art Unit: 1642 ECM JENIER 1600,2900

EISENBACH et al

Examiner: M. Yu

Appln. No.: 09/744,804

Washington, D.C.

Filed: January 30, 2001

August 16, 2002

For: TUMOR ASSOCIATED ANTIGEN

Atty. Docket: EISENBACH=3

.PESTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES

AMENDMENT

Honorable Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action of July 16, 2002, primarily in the nature of a requirement for restriction, please amend as follows:

IN THE CLAIMS

Please replace claims 26 and 32 with new amended claims 26 and 32 as follows below. A marked up version of the amended claims to show the changes made is attached hereto.

26 (Amended). The pharmaceutical composition of claim 24, wherein the composition contains an amount of said peptide effective to inhibit cancer or cancer metastases.

32 (Amended). The vaccine composition of claim 30, wherein the composition contains an amount of said peptide effective to inhibit cancer or cancer metastases.

n



Lea EISENBACH et al

Application No.: 09/744,804

Filed: June 20, 2001

Confirmation No.: 6094

Art Unit: 1642 Examiner: M. YU

RECEIVED

Washington, D.C.

Atty's Docket: EISENBACH=3

Date: August 16, 2002

OR

OR

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Sir

Transmitted herewith is a [XX] Amendment [] in the above-identified application. [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted

A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

For: TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR.

[XX] No additional fee is required.

The fee has been calculated as shown below

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 49	MINUS	** 49	0
INDEP.	* 4	MINUS	*** 4	0
FIRST DD	ECENTATION OF I	MULTIPLE	DED CLAIM	

	SMALL ENTITY					
		RATE	ADDITIONAL FEE			
	×	9	\$			
	×	42	\$			
	+	140	\$			
ADDITIONAL FEE TOTAL			\$			

ADDITIONAL RATE FFF 18 \$ \$ 84 \$ 280 TOTAL \$

OTHER THAN SMALL ENTITY

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3

- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below

Small Entity		Other Than Small Entity			
Response Filed Within	Respor	nse Filed W	ithin		
[] First - \$ 55.00	[]	First	~	\$ 110.00	
[] Second - \$ 200.00	[]	Second	-	\$ 400.00	
[] Third - \$ 460.00	[]	Third	-	\$ 920.00	
[] Fourth - \$ 720.00	[]	Fourth	-	\$ 1440.00	
Month After Time Period Set	Month /	After Time	Perio	od Set	
[] Less fees (\$) already paid for month(s) extension of time Please charge my Deposit Account No. 02-4035 in the amount of \$. Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the			<u> </u>		
Credit Card Payment Form, PTO-2038, is attached, authorizing payment in t	ine amount o	ι Φ			
A check in the amount of \$ is attached (check no.).					

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

ALLEN C YUN Registration No 37 971

Facsimile:

[] []

> (202) 737-3528 (202) 628-5197

Telephone